AI-powered for safer MRI*

At Subtle Medical, we’re dedicated to developing innovative healthcare solutions that put patient safety and wellbeing first. SubtleGAD™ (currently in the investigational stage) is a software that uses state-of-the-art deep learning technology to enable a 90% dose reduction of GBCAs (Gadolinium based contrast agents) for contrast-enhanced MRI exams while maintaining excellent image quality. There are more than 30 million contrast-enhanced MRI exams performed each year. When lower gadolinium dosage is administered for any reason, SubtleGAD software can improve image quality, diagnostic accuracy and lesion detectability. The software is compatible with any brand of MRI scanner and PACS and seamlessly integrates into the current workflow.

Award-Winning Research

Subtle’s newly patented technology was initially invented in 2017 and published in 2018 by researchers from Stanford University demonstrating feasibility. It was highlighted by RSNA as one of the key advances of the year and won an RSNA research prize. Subtle received a $1.6 million SBIR NIH Grant in 2019 to pursue research of SubtleGAD™, and in 2020, Phase II funding was awarded based on the results achieved during Phase I, as well as the scientific and technical merit of the project.

Better Patient Care

The ability to reduce gadolinium dosage by 90% when combined with SubtleGAD™ software addresses real and perceived safety and liability concerns for patients and imaging institutions around the long term effects of GBCAs used in contrast-enhanced MRI procedures.

Lowering contrast dosage has the potential to benefit tens of millions of patients, including pediatric and neonatal patients, as well as patients with chronic neurological diseases such as multiple sclerosis (MS) who have frequent contrast-enhanced MRI exams. Other potential applications include breast MRI studies, used for screening and diagnostic studies in patients with dense breasts, patients with advanced chronic kidney disease (CKD) or marginal kidney function issues who cannot currently undergo full-dose contrast-enhanced MRI, and other patients with concerns about gadolinium retention in the body.

About Subtle Medical

Subtle Medical, Inc. is a healthcare technology company with deep learning solutions that increase the quality and efficiency of medical imaging. It was named CB Insights Top AI 100 and Digital Health 150 company in 2020 and is an Nvidia Inception Award Winner. Current clinical partners include UCSF, Hoag Hospital, Mount Sinai, Sickkids, Radnet, DASA, Tiantan Hospital, and Middlesex Hospital, among others. Subtle is currently in collaboration with top-tier medical device vendors, including Siemens Healthineers, Philips (China) and several pharmaceutical partners. For more information, please visit or email

*Information on this page is for research, scientific, and educational purposes. All statements, data and results presented in these publications should be considered for investigational use.